Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Regeneron Pharmaceuticals, Inc. v. Amgen Inc.
Case Number:
1:22-cv-00697
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 30, 2023
Off Beat: Funding, Face-Offs & Food Fights
A Texas federal judge who does significant patent work will be stepping down, drug companies sparring over patents at the U.S. Supreme Court found themselves again going toe-to-toe over a different area of law, California judges provided trial tips throughout March, and the integrity of popular snacks was brought into question in Illinois. Here's what intellectual property attorneys should know about these issues and others outside their practice.
-
March 21, 2023
Amgen Must Face Regeneron's Bundling Antitrust Suit
Amgen can't escape a lawsuit accusing it of using a bundling scheme to increase the sales of its cholesterol drug Repatha and push competitors out of the market, a Delaware federal judge has ruled.
-
February 13, 2023
Court Told Not To Toss Regeneron's Amgen Bundling Suit
A magistrate judge recommended a Delaware federal court deny Amgen's attempts to toss or delay Regeneron's claims that Amgen Inc. used a bundling scheme to boost its cholesterol medication sales and said additional documents Amgen submitted should be ignored.
-
August 09, 2022
Amgen Looks To Duck Regeneron's Bundling Suit
Pharmaceutical giant Amgen asked a Delaware federal court to throw out a suit from competitor Regeneron alleging that Amgen used a bundling scheme to boost its own cholesterol medication sales while ruining the market for Regeneron's competing product.
-
May 31, 2022
Regeneron Rips Amgen's 'Bundling Scheme' Amid IP Feud
Regeneron Pharmaceuticals Inc. has launched a new antitrust lawsuit accusing Amgen of an illegal "bundling scheme" aimed at destroying the market for Regeneron's cholesterol medication Praluent and boosting sales of its main rival product, Amgen's Repatha.